复发后的骨髓瘤：新研究对患者的意义
https://vimeo.com/1160266766 德克萨斯大学MD安德森癌症中心的Krina K. Patel医学博士讨论了MAJESTIC-3临床试验中令人鼓舞的新数据，该研究针对首次复发后的多发性骨髓瘤患者，评估了两种免疫疗法联合使用的效果。她解释了这种治疗方法的工作原理、为何研究结果如此令人振奋，以及为何支持性治疗对于安全管理治疗至关重要。Patel医生还分享了实用见解，帮助患者理解这一治疗选择在其整体治疗路径中的潜在定位，在带来希望的同时，强调经过深思熟虑的个体化决策的重要性。 See More from [ACT]IVATED Multiple Myeloma Related Resources What Are Myeloma Risk Factors for Veterans and First Responders? How AI Is Shaping the Future of CAR…
Mieloma Después de la Recaída: Lo Que la Nueva Investigación Significa para los Pacientes
https://vimeo.com/1160265495 La Dra. Krina K. Patel del Centro de Cáncer MD Anderson de la Universidad de Texas analiza datos alentadores del ensayo clínico MAJESTIC-3, que estudió una combinación de dos…
Myeloma After Relapse: What New Research Means for Patients
Dr. Krina K. Patel of The University of MD Anderson Cancer Center discusses encouraging new data from the MAJESTIC-3 clinical trial, which studied a combination of two immunotherapies for people…
[ACT]IVATED Myeloma Resource Guide for Veterans and First Responders
Download Resource Guide Download Resource Guide See More from [ACT]IVATED Multiple Myeloma Share Your Feedback Create your own user feedback survey
What Are Myeloma Risk Factors for Veterans and First Responders?
https://vimeo.com/944207734 Veterans and first responders may come into contact with myeloma risk factors, but what are they? Expert Dr. Krina Patel from The University of Texas MD Anderson Cancer Center…